The largest database on outcomes with RET-directed therapy for RET-rearranged NSCLC to date confirms RET inhibitors are active in a proportion of patients, a study presented at the 2016 ASCO Annual Meeting has shown.
The 2016 consensus statement from the International Association for the Study of Lung Cancer (IASLC) describes how to best manage EGFR-mutation-positive NSCLC.
Significant sensitivity to cisplatin-based chemotherapy is signaled by the presence of low expression of SMARCA4/BRG1 in patients with earlier-stage NSCLC. Low expression of SMARCA4/BRG1 was also linked to a poor prognosis.
Combination therapy with durvalumab and tremelimumab demonstrated antitumor activity in 23% of 102 patients with lung cancer in a phase 1b trial, and toxicity was manageable.
An immunohistochemistry (IHC) test for rearrangements of the gene for anaplastic lymphoma kinase (ALK) receptor performed more accurately than another commonly used IHC assay, including reducing the rate of false positives.
Outcomes Are Comparable With Treatment Allocation Based on CGA or Performance Status and Age in Elderly Patients with NSCLCFebruary 18, 2016
Treatment allocation based on comprehensive geriatric assessment (CGA) did not improve treatment failure free survival or overall survival, but treatment toxicity was slightly reduced, in elderly patients with NSCLC.
Addition of bevacizumab to chemotherapy beyond disease progression may be effective in patients with advanced non-small cell lung cancer (NSCLC).
Younger age is associated with an increased likelihood of having a targetable genotype in patients with non-small cell lung cancer (NSCLC).
Treatment with stereotactic body radiotherapy (SBRT) was well-tolerated by patients whose non-small cell lung cancer (NSCLC) tumors were located centrally in the chest and who were not candidates for surgery.
Most patients with NSCLC that has metastasized to the brain have a dire prognosis. However, researchers have identified a subset of those patients who have a rare genetic mutation and are living significantly longer than patients without the mutation.
An analysis of an international, cooperative-led trial of patients with locally advanced NSCLC has shown that those who received IMRT had less severe lung toxicity and were able to better tolerate their chemotherapy, compared with patients who received 3-D CRT.
An international team of cancer researchers announced game-changing results in the treatment of certain lung cancers with nivolumab compared with chemotherapy in patients with non-squamous non-small cell lung cancer (NSCLC) whose disease continued to progress after first-line chemotherapy.
Nonsmokers more likely than smokers to be women and to have adenocarcinoma
A panel of five serum microRNAs has been identified as a potential biomarker to diagnose early stage non-small cell lung cancer.
A new drug is proven to offer significantly better outcomes for patients with non-small cell lung cancer who experience this debilitating side effect.
Patients with an advanced form of metastatic non-small cell lung cancer (NSCLC) may benefit from surgical resection of all or part of the lung if combined with chemotherapy and radiation therapy.
Clinical trial results showed good performance employing the investigational drug brigatinib against ALK-positive non-small cell lung cancer (NSCLC).
Individuals with squamous non-small cell lung cancer (NSCLC) fared better when receiving nivolumab when compared to those receiving more standard chemotherapy, according to a recent clinical trial.
Stereotactic ablative radiotherapy (SABR) offers better overall survival than surgery in early lung cancerJune 02, 2015
Patients with operable stage I non-small cell lung cancer can achieve better overall survival rates if treated with stereotactic ablative radiotherapy (SABR) opposed to the current standard therapy.
Researchers urge for new targeted inhibitors and combinations to combat tumors' constant and varied molecular adaptation.
This developing technology allows serial monitoring to better gauge response to treatment and prognosis for patients with non-small cell lung cancer.
Research indicates that a known mutation in non-small cell lung cancer (NSCLC) is also present in small cell lung cancer, implying that some effective treatments for NSCLC can also be used on the more aggressive form of the disease.
Survival longer in patients with early stage non-small cell lung cancer (NSCLC) with low tumor metabolic activityApril 22, 2015
Increased overall survival and more time before tumor recurrence is associated with low presurgery uptake of a labeled glucose analogue in the primary tumor of patients with stage I non-small cell lung cancer.
A new online tool uses a patient's molecular characteristics and provides feedback from an expert panel to help oncologists with therapeutic decision-making for advanced non-small cell lung cancer (NSCLC).
A study examined the feasibility of using circulating free DNA (cfDNA) from blood samples of patients with advanced non-small cell lung cancer as a surrogate for tumor biopsies.
An existing drug may assist patients with non-small cell lung cancer (NSCLC) that shows chemotherapy resistance.
Stereotactic body radiation therapy (SBRT) plus chemotherapy improves survival among patients with stage 4 lung cancerJanuary 20, 2015
Combining stereotactic body radiation therapy (SBRT) with a specific chemotherapy regimen more than doubled survival rates for certain patients with stage 4 lung cancer, according to recent research data.
Researchers have found that an FDA-approved therapy could be effective in treating both older and African American patients with advanced lung cancer who may not be candidates for chemotherapy.
A new drug that targets common cancer-causing genetic mutations in patients with non-small cell lung cancer (NSCLC), and a type of the mutation responsible for treatment resistance, has shown promising results in a phase I/II clinical trial.
An oral drug called ASP8273 caused tumor shrinkage in patients in a phase I clinical trial, according to research presented at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|